F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH and Abbott are Dominating the Global Prostate Cancer Diagnostics Market in 2020

Global Prostate Cancer Diagnostics Market is expected to grow with the CAGR of 20.1% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-prostate-cancer-diagnostics-market

Global prostate cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.     

The major players dealing in prostate cancer diagnostics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, In May 2020, F. Hoffmann-La Roche Ltd officially announced the acquisition of Stratos Genomics. This acquisition leads to the development of DNA-based sequencing for diagnostics use. This enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation of the company.

FF. Hoffmann-La Roche Ltd is the dominating player in prostate cancer diagnostics market. The other key players existing in the market includes ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., Myraid Genetics, Inc., DiaSorin S.p.A, Beckman Coulter, Inc. (a subsidiary of Danaher), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH among others domestic.

Prostate Cancer Diagnostics MarketF. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd was incorporated in 1896 and is headquartered in Basel, Schweiz. Company is focusing on fitting treatments to patients and providing the right therapy for the group of patient. Company is exclusively concentrating on ophthalmology, diabetes and oncology division. The business segments are pharmaceuticals and diagnostics among which diagnostic is the market focused segment. The product categories provided by the company are anatomic pathology, clinical chemistry & immunochemistry, companion diagnostic, decision support, diabetes care, digital diagnostics, donor screening, hemostasis, lab automation & software solutions, molecular diagnostic, point of care, urinalysis among which anatomic pathology, clinical chemistry & immunochemistry are the market focused categories.

For instance;

  • In December 2017, F. Hoffmann-La Roche Ltd and Ignyta officially announced their merger in medicine and oncology. This agreement crated an opportunity for both the players to serve more customers worldwide leading to more strong financials.

The company has presence across Asia-Pacific, Europe, Middle East Africa, North America and South America and various subsidiaries such as Productos Roche S.A (Colombia), Roche Diabetes Care France SAS (France), Roche Georgia LLC (Georgia), Roche Pharmaceuticals (Israel) Ltd. (Israel), Roche Diagnostics S.p.A. (Italy), Roche Kenya Limited (Kenya), and others.

Siemens Healthcare GmbH

Siemens Healthcare GmbH is headquartered in Forchheim, Germany. The company provides laboratory diagnostics, medical imaging, digital ecosystem, reading solutions among others worldwide. The business segments are imaging, diagnostics & advanced therapies among which diagnostics, imagining are the market focused segments. The product categories of the company are medical imaging, laboratory diagnostics, point of care testing, digital health solutions, services & consulting, clinical specialties, accessories, OEM & electronics & healthcare IT among which laboratory diagnostics, medical imaging are the market focused categories.

  • In October 2020, Siemens Healthcare GmbH announced that they have launched Biograph Vision Quadra Extended Axial FoV PET/CT Scanner. This scanner is the industry’s most sensitive extended field view scanner designed for clinical and research purposes. The product is of high clinical use and will increase the demand for cancer diagnostic procedure and will increase the revenue for the company

The company has wide presence across North America, Europe & Asia and various subsidiaries such as Fast Track Diagnostics Ltd. (Europe), Siemens Healthcare Medical Solutions Limited (Germany), Siemens Healthcare Germany (Germany), among others.


Abbott was founded in 1888 and is headquartered in Florida, U.S. The company focused on helping people lives their healthiest possible lives. The business segments of the company are established pharmaceuticals products, nutritional, diagnostics, medical devices, other among which diagnostics is the market focused category.  The product categories are cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition, and medicines among which diagnostics is the market focussed category. 

  • In March 2019, Abbott diagnostic system is likely to expand for molecular diagnosis testing. Alinity diagnostic system was set to help the healthcare professional for better diagnosis in cancer and other diseases. This will help to expand the product usage and will increase the demand for the product in near future for cancer diagnosis. 

The company has presence in Asia-Pacific, Greater China, Europe, Middle East and Africa, The Americas among which Abbott Administration Inc. (Delaware), Abbott Bioresearch Center, Inc. (Delaware), Abbott Diabetes Care Sales Corporation (Delaware), Abbott Home Infusion Services of New York, Inc. (New York), and Abbott Laboratories Inc. (Delaware) are the market focussed categories.